Innovhem to present New data on single-cell quantification of HbF and HbS at the 2024 ASH Annual Meeting.
One poster presentation to feature new data, highlighting the single-cell quantification of HbF and HbS on patients treated with hydroxyurea.
Innovhem is a French company developing first-in-class innovations to improve the clinical management of patients with Sickle Cell Disease. Today, Innovhem announced that data from our FCDREP studies on single-cell quantification of HbF and HbS will be presented at the 66th Annual Meeting of the ASH in San Diego, as well as online.
This presentation will highlight the value of using single-cell Hb quantification to better understand the mechanisms of treatments aimed at increasing HbF expression, as well as their evaluation and patient follow-up.
Paris, France – November 15th, 2024
Details of the poster presentations of Innovhem at ASH annual meeting 2024:
Abstract #1105
• Title: Single Cell Hemoglobin Quantification Reveals HbF and HbS Increases in Sickle Erythrocytes from Patients Treated with Hydroxyurea
• Presenting Author: Pablo Bartolucci, MD,PhD, University Paris-Est-Creteil, IMRB, Henri Mondor University Hospitals, APHP, Sickle Cell Referral Center-UMGGR, Creteil, France
• Program: Oral and Poster Abstracts. Session: 113. Sickle Cell Disease, Sickle Cell Trait, and Other Hemoglobinopathies, Excluding Thalassemias: Basic and Translational: Poster I
Hematology Disease Topics & Pathways: Research, Sickle Cell Disease, Translational Research, Hemoglobinopathies, Diseases
• Presentation date and time: Saturday, December 7, 2024, 5:30 PM-7:30 PM
